Alamar Biosciences Q3 2026 net loss widens 66% to $13.3 million as revenue rises 68% to $33.5 million
ALMR•Alamar Biosciences reported Q3 2026 revenue of $33.5 million, up 68% year over year, and a net loss of $13.3 million, up 66%. It raised FY26 revenue guidance to $121 million–$123 million from $116 million–$120 million.
1. Quarterly results
Alamar Biosciences’ Q3 2026 revenue rose 68% year over year to $33.5 million, while its net loss widened 66% to $13.3 million. Consumable revenue increased 79% to $17.8 million, and total operating expenses climbed 81% to $35.8 million.
2. Guidance and study
The company raised FY26 revenue guidance to $121 million–$123 million from $116 million–$120 million. Its NULISA platform was selected to profile 80,000 samples for a UK Biobank neurodegeneration study.
